Biogen, Isis collaborate on neurological disease drug discovery

Biogen Idec and Isis Pharmaceuticals have announced their fourth strategic collaboration in two years – this time, to advance the treatment of neurological diseases.

Under terms of the agreement, Isis will receive US $100 million upfront, with potential future milestone payments and license fees, plus royalties. The deal will combine Biogen's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological diseases. Biogen will gain exclusive rights to the use of Isis' antisense technology, as part of the six-year research collaboration.

"This strategic alliance with Isis builds on our existing relationship and combines the unique strengths of each partner to significantly advance the treatment of serious neurological diseases. Antisense is a validated technology that we believe will help build our pipeline of antisense, small molecule and biologics programs, strengthening our leadership in neurology."

Douglas E. Williams, Ph.D., Biogen Idec's executive vice president of research and development.

Biogen and Isis will work closely together to select and validate neurological disease targets and conduct drug discovery activities. Isis will be primary responsible for drug discovery and early development of antisense therapies, while Biogen will be responsible for the creation and development of small molecule treatments and biologics. In each case, Biogen will determine the molecular modality best suited for advancement through clinical development. Biogen will also be responsible for later stage development and commercialization of all drugs arising from the collaboration.